Byondis World ADC Highlights:

(MENAFN- Byondis) Nijmegen, the Netherlands – 7 October 2021 – Byondis BV, an independent, clinical stage biopharmaceutical company creating precision medicines, announced that results of its pivotal Phase III TULIP® study involving ADC [vic-]trastuzumab duocarmazine (SYD985) will be presented at the 12th World ADC San Diego Digital Edition conference, October 11-14. The trial, which compared SYD985 to physician's choice (PC) treatment, demonstrated a statistically significant improvement in progression-free survival (PFS) over PC. The company will also present on the preclinical profile of ADC SYD1875 and on its proprietary, site-specific ADC conjugation platform, ByonShieLD®, which is employed in SYD1875.
Details follow:
• Monday, 11 October, 12:30 PM EDT / 6:30 PM CET
o “Preclinical Profile of SYD1875, a Novel Site-Specifically Conjugated Anti-5T4 Antibody Drug Conjugate,” Patrick Groothuis, Ph.D., Byondis Principal Scientist - In Vivo Pharmacology, Toxicology, Drug Metabolism & Pharmacokinetics
• Tuesday, 12 October, 12:00 PM EDT / 6:00 PM CET
o “ByonShieLD®, A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines,” Ruud Coumans, Ph.D., Byondis Project Leader, Antibody-Drug Conjugates
• Wednesday, 13 October, 8:30 AM EDT / 12:30 PM CET
o “Primary Outcome of the Phase III SYD985.002/TULIP® Study Comparing [vic-]trastuzumab duocarmazine to Physician’s Choice Treatment in Patients with Pre-treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,” Evelyn van den Tweel, Ph.D., Byondis Project Leader, Clinical Development
About Byondis
Driven to improve patients’ lives, Byondis is an independent, privately held, clinical stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) using proprietary molecular concepts, such as ByonZine®, its duocarmazine linker-drug (LD) technology, and ByonShieLD®, its site-specific conjugation technology, to create next generation antibody-drug conjugates (ADCs).
Byondis’ broad development portfolio comprises preclinical as well as early- and late-stage clinical programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985). The company has a dedicated team of about 400 employees, including highly educated scientists and skilled technicians working in state-of-the-art R&D and Good Manufacturing Practice manufacturing facilities on its Nijmegen campus in the Netherlands. Byondis regularly collaborates with leading, global biotechnology and pharmaceutical companies, as well as many academic research institutions. For more information, visit